TABLE 3.
Clinical impact based on mNGS results in 1,473 samples
| Clinical impacta | No. (%) of samples |
||
|---|---|---|---|
| Immunosuppression (n = 247) | Nonimmunosuppression (n = 1,226) | Total (n = 1,473) | |
| Positive impact | 67 (27.1) | 139 (11.3) | 206 (14.0) |
| New diagnosis | 56 (22.7) | 104 (8.5) | 160 (10.9) |
| Medication added | 42 (17.0) | 62 (5.1) | 104 (7.1) |
| Antibiotics | 19 (7.7) | 32 (2.6) | 51 (3.5) |
| Antivirals | 19 (7.7) | 22 (1.8) | 41 (2.8) |
| Antifungal | 0 | 0 | 0 |
| Supportive therapy | 4 (1.6) | 7 (0.6) | 11 (0.8) |
| Medication changed | 14 (5.7) | 37 (3.0) | 51 (3.5) |
| Escalated | 5 (2.0) | 10 (0.8) | 15 (1.0) |
| De-escalated | 4 (1.6) | 8 (0.6) | 12 (0.8) |
| Discontinued | 5 (2.0) | 19 (1.6) | 24 (1.6) |
| Negative impact | 3 (1.2) | 8 (0.7) | 11 (0.8) |
| Unnecessary testing | 3 (1.2) | 7 (0.6) | 10 (0.7) |
| Unnecessary therapy | 0 | 1 (0.1) | 1 (0.1) |
| No impact | 175 (70.9) | 1,073 (87.5) | 1,248 (84.7) |
| Unknown | 2 (0.8) | 6 (0.5) | 8 (0.5) |
a
Samples with more than one impact were calculated separately.